Fighting COVID-19 with topical formulations
The COVID-19 pandemic has driven tremendous innovation within the pharmaceutical industry over the last year. Topical formulators were no exception, with many interested in developing effective solutions for fighting the SARS-CoV-2 virus. Tioga Research has beenhelping groups develop viricidal topical formulations for administration to one or more mucosal surfaces.
BASF developed a hand wash based on polyvinylpyrrolidone (PVP)-iodine, the active ingredient considered the gold standard in the medical community for sanitizing prior to surgical procedures. PVP-Iodine presented as a mouth gargle and topical spray may be potential candidates to combat viruses as well, and clinical data significant enough to validate its performance against SARS-CoV-2 are being developed, according to Benjamin Goodyear, global technical marketing manager for BASF’s Pharma Solutions group.
Tergus Pharma entered an agreement with Phenom Pharmaceuticals to develop a unique delivery solution for intranasal administration of a unique API with the potential to prevent viral infection. “In this partnership, we are leveraging our technology in topical pharmaceutical R&D and manufacturing,” says Vijendra Nalamothu, chairman and CEO of Tergus Pharma.